Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Down 62.6% in December

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 10,400 shares, a decrease of 62.6% from the December 15th total of 27,800 shares. Based on an average trading volume of 273,300 shares, the short-interest ratio is presently 0.0 days.

Biodexa Pharmaceuticals Trading Up 2.2 %

Shares of BDRX traded up $0.10 during midday trading on Tuesday, reaching $4.40. 1,221 shares of the stock were exchanged, compared to its average volume of 14,315. Biodexa Pharmaceuticals has a 52 week low of $3.50 and a 52 week high of $74.00. The firm has a 50 day moving average price of $4.60.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.